AzTrials
AzTrials

Triple Negative Breast CancerPhase 2NCT03184558

Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With TNBC

A Phase 2 study testing Bemcentinib; pembrolizumab in people with Triple Negative Breast Cancer and Inflammatory Breast Cancer Stage IV, run by BerGenBio ASA at 17 sites in 4 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

This is an open label, single arm, multi-centre phase II study to assess the anti-tumour activity and safety of bemcentinib (BGB324) in combination with pembrolizumab in participants with previously treated, locally advanced and unresectable, or metastatic TNBC or TN-IBC. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Bemcentinib; pembrolizumab
Could I receive a placebo?
No, everyone receives an active treatment
How many people
29 participants
Where
17 sitesin 4 countries
Study dates
26 Jul 2017to 20 Aug 2018
Phase
Phase 2
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Provision of signed informed consent.
  • Male and non-pregnant females who are aged 18 years or older at the time of provision of informed consent.
  • Histopathologically or cytologically documented TNBC or TN-IBC. Tumors must have been confirmed negative for ER and partial response (PR) by immunohistochemistry (IHC) (<1% positive tumor nuclei, as per ASCO-CAP guideline recommendations) and negative for human epidermal growth factor receptor 2 (HER2) by IHC or fluorescent or chromogenic in situ hybridization (FISH or CISH). Patients with equivocal HER2 results by IHC should have their negativity status confirmed by FISH.
  • Locally advanced and unresectable or metastatic TNBC or triple negative inflammatory breast cancer.
  • Received one or more prior therapies for TNBC or inflammatory breast cancer in the metastatic setting, and prior treatment (metastatic or (neo) adjuvant) must have included a prior taxane and/or anthracycline-based therapy.
  • Has measurable disease as defined by RECIST 1.1 on computed tomography (CT) or magnetic resonance imaging (MRI) and as determined by the site study team. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions.
Show all 21Show fewer
  • Provision of suitable tumor tissue for the analysis of Axl kinase expression and PD-L1 expression.
  • Eastern Cooperative Oncology Group (ECOG) performance score 0 or 1.
  • Life expectancy of at least 3 months.
  • Adequate organ function confirmed at Screening and within 10 days of initiating treatment, as evidenced by:
  • Platelet count ≥100,000 /mm3;
  • Hemoglobin ≥9.0 g/dL (≥5.6 mmol/L);.
  • Absolute neutrophil count (ANC) >1,500 /mm^3;
  • Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤2.5 times the upper limit of normal (ULN), or ≤5 times the ULN for patients with liver metastases;
  • Total bilirubin ≤1.5 times the ULN, or direct bilirubin <ULN for patients with total bilirubin levels >1.5xULN;
  • Creatinine ≤1.5 times the ULN and calculated creatinine clearance >60 mL/min (by Cockcroft Gault formula);
  • International Normalized Ratio (INR) or Prothrombin Time (PT) ≤1.5 times the ULN and Activated Partial Thromboplastin Time (aPTT) ≤1.5 times the ULN. Note: If patient is receiving anticoagulant therapy, then PT or PTT must be within therapeutic range of intended use of anticoagulants;
  • Lactate dehydrogenase (LDH) ≤2.5 times the ULN.
  • Female patients of childbearing potential must have a negative pregnancy test (either urine or serum pregnancy test) within 72 hours prior to the first dose of study treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  • Have resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If the patient received major surgery or radiation therapy of >30 Gy, they must have recovered from the toxicity and/or complications from the intervention.
  • Patients of reproductive potential must be willing to practice highly effective methods of contraception throughout the study and for 120 days after the last dose of study medication. Abstinence is acceptable if this is the usual lifestyle of the patient.

Who cannot join

  • Has disease that is suitable for local therapy administered with curative intent.
  • More than 3 previous lines of therapy in the metastatic setting.
  • Has received prior therapy with an immunomodulatory agent.
  • Has a known additional malignancy that is progressing or requires active treatment. Note: Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • History of the following cardiac conditions:
Show all 37Show fewer
  • Congestive cardiac failure of >Grade II severity according to the New York Heart Association (NYHA);
  • Ischemic cardiac event including myocardial infarction within 3 months prior to first dose;
  • Uncontrolled cardiac disease, including unstable angina, uncontrolled hypertension (i.e. sustained systolic BP >160 mmHg or diastolic BP >90 mmHg), or need to change medication due to lack of disease control within 6 weeks prior to the provision of consent;
  • History or presence of sustained bradycardia (≤55 BPM), left bundle branch block, cardiac pacemaker or ventricular arrhythmia. Note: Patients with a supraventricular arrhythmia requiring medical treatment, but with a normal ventricular rate are eligible;
  • Family history of long QTc syndrome; personal history of long QTc syndrome or previous drug-induced QTc prolongation of at least Grade 3 (QTc >500 ms).
  • Abnormal left ventricular ejection fraction on echocardiography or Multi Gated Acquisition Scan (MUGA) (less than the lower limit of normal for a patient of that age at the treating institution or <45%, whichever is lower).
  • Current treatment with any agent known to cause Torsades de Pointes which cannot be discontinued at least five half-lives or two weeks prior to the first dose of study treatment.
  • Screening 12-lead ECG with a measurable QTc interval according to Fridericia's correction >450 ms.
  • Is currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of study treatment.
  • Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., ≤Grade 1 or at baseline) from AEs due to a previously administered agent.
  • Received an anti-cancer monoclonal antibody (mAb) within 4 weeks prior to the first dose of study treatment or who has not recovered (i.e. ≤Grade 1 or baseline) from AEs due to agents administered more than 4 weeks earlier.
  • Major surgery within 28 days prior to start of study treatment and failure to have recovered adequately from the toxicity and/or complications from the intervention prior to the first dose of study treatment.
  • Received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including granulocyte-colony stimulating factor [G-CSF], Granulocyte-macrophage colony-stimulating factor [GM-CSF] or recombinant erythropoetin) within 4 weeks prior to the first dose of study treatment.
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.
  • Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs).
  • Known history of human immunodeficiency virus (HIV 1/2 antibodies)
  • Has known active infection with Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., Hepatitis C virus (HCV) RNA (qualitative) is detected).
  • Has received a live-virus vaccination within 30 days of planned treatment start. Note: Seasonal flu vaccines that do not contain live virus are permitted.
  • Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis.
  • Has a history of interstitial lung disease.
  • Inability to swallow or tolerate oral medication.
  • Existing gastrointestinal disease affecting drug absorption such as celiac disease or Crohn's disease, or previous bowel resection which is considered to be clinically significant or could interfere with absorption.
  • Known lactose intolerance.
  • Requires vitamin K antagonists. Note: Patients receiving low doses prescribed to maintain the patency of venous access devices may be included. Factor Xa antagonists are permitted.
  • Treatment with any of the following: histamine receptor 2 inhibitors, proton pump inhibitors or antacids within 7 days of start of study treatment.
  • Treatment with any medication which is predominantly metabolized by CYP3A4 and has a narrow therapeutic index.
  • Known severe hypersensitivity (≥Grade 3) to bemcentinib, pembrolizumab, and/or any of their excipients.
  • Has an active infection requiring systemic therapy (apart from cutaneous infections).
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that, in the opinion of the Investigator, might confound the results of the trial, interfere with the patient's participation and compliance in the trial, or means it is not in the best interests of the patient to participate.
  • Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting from Screening through to 120 days after the last dose of study treatment.
  • Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.

Trial locations and contacts

17 sites in 4 countries.

17 sites in 4 countries

Spain7 sites

  • University General Hospital of Alicante

    Alicante, 03010

  • Hospital Clinic i Provincial de Barcelona

    Barcelona, 08036

  • Hospital Universitario Germans Trias i Pujol - Institut Catala d'Oncologia

    Barcelona, 08916

  • Hospital Universitario Amau de Vilanova de Lieda, Servicio de Oncologia

    Lleida, 25198

  • Hospital General Universitario Gregorio Maranon

    Madrid, 28007

  • Hospital Universitario Ramon y Cajal

    Madrid, 28034

  • Hospital Universitario Miguel Servet

    Zaragoza, 50009

Other trials in Spain

United States5 sites

  • City of Hope Cancer Center

    Duarte, California, 91010-3012

  • Saint Luke's Cancer Institute

    Kansas City, Missouri, 64111

  • Dartmouth-Hitchcock Medical Center

    Lebanon, New Hampshire, 03756

  • Magee-Womens Hospital, UPMC Cancer Pavilion

    Pittsburgh, Pennsylvania, 15232-1309

  • Sharp memorial Hospital, 7901 Frost Street,

    San Diego, California, 92123-2701

Other trials in United States

United Kingdom4 sites

  • Beatson West of Scotland Cancer Centre

    Glasgow, Scotland, G12 0YN

  • Imperial College Healthcare NHS Trust, Charing Cross Hospital

    London, W6 8RF

  • The Christie NHS Foundation Trust

    Manchester, M20 4BX

  • Nottingham University Hospitals, City Campus, Hucknall Road

    Nottingham, NG5 1 PB

Other trials in United Kingdom

Norway1 site

  • Haukeland University Hospital

    Bergen, 5021

Other trials in Norway

About this study

Official title: A Phase II, Multi Centre Study of BGB324 in Combination With Pembrolizumab in Patients With Previously Treated, Locally Advanced and Unresectable or Metastatic Triple Negative Breast Cancer (TNBC) or Triple Negative Inflammatory Breast Cancer (TN-IBC)

This is an open label, single arm, multi-centre phase II study to assess the anti-tumour activity and safety of bemcentinib (BGB324) in combination with pembrolizumab in participants with previously treated, locally advanced and unresectable, or metastatic TNBC or TN-IBC. The primary objective is objective response rate.

Being tested
Bemcentinib; pembrolizumab
Keywords
bemcentinib, TNBC, pembrolizumab, Keytruda, BGB324
Medical subject headings
Triple Negative Breast Neoplasms, Inflammatory Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Bemcentinib; pembrolizumabDrug

    Also called BGB324; Keytruda

    Bemcentinib is a selective Axl kinase inhibitor; pembrolizumab is a programmed death receptor-1 (PD-1) inhibitor.

Study groups in NCT03184558
Study groupRoleWhat they receive
Bemcentinib (BGB324) + pembrolizumabExperimentalParticipants received Bemcentinib (BGB324) capsules orally once daily as a loading dose of 400 milligram (mg) on Days 1, 2, and 3. A dose of 200 mg pembrolizumab was given by intravenous infusion over 30 minutes every 3 weeks in all participants. Dosing of both drugs commenced on Day 1. On days when both BGB324 and pembrolizumab were given, pembrolizumab was given first and participants were observed for 1 hour after the end of infusion before BGB324 was administered. From Day 4 onward, participants received a daily maintenance dose of 200 mg along with Pembrolizumab 200 mg intravenous (IV) infusion over 30 minutes every 3 weeks until disease progression, until an unacceptable toxicity occurred that required treatment withdrawal or withdrawal of consent or until 106 weeks had passed.
Receives: Drug: Bemcentinib; pembrolizumab

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Objective Response Rate (ORR)

    ORR is defined as the percentage of evaluable participants who had at least one confirmed overall response of complete response (CR) or partial response (PR) according to the modified Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. CR: Disappearance of all target lesions (TLs) since baseline, any pathological lymph nodes selected as TLs must have a reduction in short axis to less than (<) 10 millimeter (mm). PR: At least a 30 percent decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters.

    Measured: Until disease progression or death or withdrawal of consent whichever comes first, up to end of study (Up to 1 year)

Secondary outcomes (4)

  1. Duration of Response (DOR)

    DOR is defined as the time from the date of first documented response until date of documented progression or death in the absence of disease progression (PD); the end of response should coincide with the date of progression or death from any cause. PD per modified RECIST 1.1 defined as: at least a 20 percent increase in the sum of diameters of TLs and an absolute increase of at least 5 mm, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study).

    Measured: Until disease progression or death or withdrawal of consent whichever comes first, up to end of study (Up to 1 year)

  2. Disease Control Rate (DCR)

    DCR is defined as the percentage of participants with a confirmed CR, PR, or stable disease (SD). CR: Disappearance of all target lesions (TLs) since baseline, any pathological lymph nodes selected as TLs must have a reduction in short axis to < 10 mm. PR: At least a 30 percent decrease in the sum of the diameters of TLs, taking as reference the baseline sum of diameters. SD per modified RECIST 1.1 defined as: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Measured: Until disease progression or death or withdrawal of consent whichever comes first, up to end of study (Up to 1 year)

  3. Progression-free Survival (PFS)

    PFS was defined as the duration from start of treatment until the date of radiological disease progression (the date on which the confirmed progression was initially observed) or the date of death (regardless of cause of death), whichever was earlier.

    Measured: Until disease progression or death or withdrawal of consent whichever comes first, up to end of study (Up to 1 year)

  4. Overall Survival (OS)

    OS was defined as the time from the first dose of study treatment until the date of death (from any cause and irrespective of any subsequent anti-cancer treatment given).

    Measured: Until disease progression or death or withdrawal of consent whichever comes first, up to end of study (Up to 1 year)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Jun 2017
  2. Study start26 Jul 2017
  3. Primary completion20 Aug 2018
  4. Study completion20 Aug 2018

Why it stopped: Based on planned futility assessment

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
Extension to Simon's 2-stage design allowing termination at the end of Stage 1 for either futility or efficacy.
Masking
None (open label)
Enrolment
29 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03184558
Sponsor's protocol ID
BGBC007
Other IDs
MK-3475 PN530, 2016-003608-30, 2016
Status last verified
Oct 2021
First submitted
30 May 2017
Last updated
9 Nov 2021
Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
Individual data sharing
Yes: Individual participant data that underlie the results reported in the article, after deidentification \[text, tables, figures and appendices\].

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Bemcentinib; pembrolizumab in people with Triple Negative Breast Cancer and Inflammatory Breast Cancer Stage IV, run by BerGenBio ASA at 17 sites in 4 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 21 inclusion and 37 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 9 Nov 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 17 sites in Spain, United States, United Kingdom, Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 9 Nov 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Objective Response Rate (ORR) (time frame: Until disease progression or death or withdrawal of consent whichever comes first, up to end of study (Up to 1 year)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03184558.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 9 Nov 2021.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in